NEW YORK / Jul 24, 2023 / Business Wire / DocGo Inc., a leading provider of last-mile mobile health services (Nasdaq: DCGO), today announced that the company will report results for the second quarter ended June 30, 2023, after the markets close on Monday, August 7th. Management will host a conference call for analysts and investors at 5:00pm ET on that day.
Conference call and webcast details:
Monday, August 7th, 5:00pm EDT
1-877-407-0784 (U.S.)
1-201-689-8560 (international)
Conference ID: 13739932
To access the Call me™ feature, which avoids the need to wait for an operator, click here.
The webcast can be accessed under Events on the Investors section of the company’s website, https://ir.docgo.com/.
About DocGo
DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo disrupts the traditional four-wall healthcare system by providing high quality, highly affordable care to patients where and when they need it. DocGo's proprietary, AI-powered technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit docgo.com.
| Last Trade: | US$1.50 |
| Daily Change: | -0.06 -3.85 |
| Daily Volume: | 588,526 |
| Market Cap: | US$148.650M |
May 08, 2025 February 27, 2025 February 19, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
